Generic Version of Epivir Launched


Mylan has launched lamivudine tablets USP, 150 mg and 300 mg, which are the equivalent of ViiV Healthcare's Epivir tablets.

Mylan has launched lamivudine tablets USP, 150 mg and 300 mg, which are the equivalent of ViiV Healthcare’s Epivir tablets.

Lamivudine is a nucleoside analogue reverse transcriptase inhibitor designed to treat HIV-1 infection in combination with other antiretroviral agents.

Patients should be aware that the HIV treatment has been linked with lactic acidosis and fatty liver disease. In addition, patients who are coinfected with HIV and hepatitis B virus may have severe acute exacerbations of hepatitis B when they discontinue lamivudine.

The treatment had US sales of around $27 million for the fiscal year ending on December 31, 2015, according to IMS Health.

Mylan announced the FDA’s approval of its abbreviated new drug application (ANDA) on April 6, 2016.

To date, Mylan has 265 ANDAs pending with the FDA that are worth around $110 billion in annual brand sales.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.